Processing

Please wait...

Settings

Settings

Goto Application

1. WO2014173374 - TAMOXIFEN DERIVATIVES FOR TREATMENT OF NEOPLASTIC DISEASES, ESPECIALLY WITH HIGH HER2 PROTEIN LEVEL

Publication Number WO/2014/173374
Publication Date 30.10.2014
International Application No. PCT/CZ2014/000035
International Filing Date 07.04.2014
IPC
C07F 9/54 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
FACYCLIC, CARBOCYCLIC, OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
9Compounds containing elements of Groups 5 or 15 of the Periodic System
02Phosphorus compounds
28with one or more P-C bonds
54Quaternary phosphonium compounds
A61P 35/04 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
04specific for metastasis
A61K 31/662 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
66Phosphorus compounds
662Phosphorus acids or esters thereof having P-C bonds, e.g. foscarnet, trichlorfon
CPC
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 35/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
02specific for leukemia
A61P 35/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
04specific for metastasis
A61P 43/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
C07F 9/5442
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
9Compounds containing elements of Groups 5 or 15 of the Periodic System
02Phosphorus compounds
28with one or more P—C bonds
54Quaternary phosphonium compounds
5442Aromatic phosphonium compounds (P-C aromatic linkage)
C07F 9/5449
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
9Compounds containing elements of Groups 5 or 15 of the Periodic System
02Phosphorus compounds
28with one or more P—C bonds
54Quaternary phosphonium compounds
5449Polyphosphonium compounds
Applicants
  • SMART BRAIN S.R.O. [CZ]/[CZ]
  • BIOTECHNOLOGICKÝ ÚSTAV AV ČR, V.V.I. [CZ]/[CZ]
  • KKCG PLC [CY]/[CY]
  • NEUŽIL, Jiří [CZ]/[CZ]
Inventors
  • NEUŽIL, Jiří
  • ŠTURSA, Jan
  • WERNER, Lukáš
Agents
  • ŠKAMPOVÁ, Kristina
Priority Data
PV 2013-30824.04.2013CZ
PV 2014-6629.01.2014CZ
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) TAMOXIFEN DERIVATIVES FOR TREATMENT OF NEOPLASTIC DISEASES, ESPECIALLY WITH HIGH HER2 PROTEIN LEVEL
(FR) DÉRIVÉS DE TAMOXIFÈNE DANS LE TRAITEMENT DE MALADIES NÉOPLASIQUES, SPÉCIALEMENT AVEC UNE TENEUR ÉLEVÉE EN PROTÉINE HER2
Abstract
(EN) The subject of the invention are new mitochondrially targeted E/Z isomers of aliphatic triphenylphosphonium derivatives of tamoxifen where the aliphatic chain is alkyl or alkenyl, and their corresponding tertiary amine salts and/or their mixture (MitoTAX). Alkyl triphenylphosphonium derivatives of tamoxifen have the general formula (I), where n=8 to 12 and where Z is selected from the group of organic salts or inorganic salts. Alkenyl triphenylphosphonium derivatives of tamoxifen have the general formula IA, where n = 6 to 10 and where Z has the above mentioned meaning. These compounds are applicable for the treatment of neoplastic disease, especially those with high HER2 protein levels. The drug for the treatment of neoplastic diseases according to the invention contains at least one E/Z isomer of aliphatic triphenylphosphonium derivatives of tamoxifen of the general formula (I) and/or IA or their corresponding salts of tertiary amine.
(FR) La présente invention a pour objet de nouveaux isomères E/Z à ciblage mitochondrial de dérivés de triphénylphosphonium aliphatiques du tamoxifen, où la chaîne aliphatique est une chaîne alkyle ou alcényle, et leurs sels d'amine tertiaire correspondants et/ou leur mélange (MitoTAX). Les dérivés d'alkyltriphénylphosphonium du tamoxifène répondent à la formule générale (I), où n = 8 à 12 et Z est choisi dans le groupe constitué par les sels organiques et inorganiques. Les dérivés d'alcényltriphénylphosphonium du tamoxifène répondent à la formule générale IA, où n = 6 à 10 et Z prend la valeur susmentionnée. Ces composés sont applicables au traitement d'une maladie néoplasique, spécialement de celles qui présentent des teneurs élevées en protéine HER2. Le médicament destiné au traitement de maladies néoplasiques selon l'invention contient au moins un isomère E/Z de dérivés de triphénylphosphonium aliphatiques du tamoxifène de formule générale (I) et/ou IA ou de leurs sels correspondants d'amine tertiaire.
Related patent documents
UAa201510642This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
GE13996/1This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
MDa 2015 0117This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
Latest bibliographic data on file with the International Bureau